Vivoryon Therapeutics NV
AEX:VVY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Vivoryon Therapeutics NV
EPS (Diluted)
Vivoryon Therapeutics NV
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Vivoryon Therapeutics NV
AEX:VVY
|
EPS (Diluted)
€0
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
10%
|
|
|
BioNTech SE
NASDAQ:BNTX
|
EPS (Diluted)
-€4
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
CureVac NV
NASDAQ:CVAC
|
EPS (Diluted)
€0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Immatics NV
NASDAQ:IMTX
|
EPS (Diluted)
-€1
|
CAGR 3-Years
N/A
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
Biotest AG
XETRA:BIO
|
EPS (Diluted)
€0
|
CAGR 3-Years
24%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
Formycon AG
XETRA:FYB
|
EPS (Diluted)
-€7
|
CAGR 3-Years
-81%
|
CAGR 5-Years
-99%
|
CAGR 10-Years
N/A
|
|
Vivoryon Therapeutics NV
Glance View
The company is headquartered in Halle, Sachsen-Anhalt and currently employs 16 full-time employees. The company went IPO on 2014-10-27.
See Also
What is Vivoryon Therapeutics NV's EPS (Diluted)?
EPS (Diluted)
-0.8
EUR
Based on the financial report for Dec 31, 2024, Vivoryon Therapeutics NV's EPS (Diluted) amounts to -0.8 EUR.
What is Vivoryon Therapeutics NV's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
10%
Over the last year, the EPS (Diluted) growth was 29%. The average annual EPS (Diluted) growth rates for Vivoryon Therapeutics NV have been -8% over the past three years , -15% over the past five years , and 10% over the past ten years .